Development and Initial Validation of the Thyroid Cancer Module of the M. D. Anderson Symptom Inventory

被引:49
|
作者
Gning, Ibrahima [1 ]
Trask, Peter C. [3 ]
Mendoza, Tito R. [1 ]
Harle, Margaret T. [1 ]
Gutierrez, Karla A. [1 ]
Kitaka, Sheila A. [2 ]
Sherman, Steven I. [2 ]
Cleeland, Charles S. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
[3] Pfizer Inc, Global Outcomes Res, New London, CT USA
关键词
Symptoms; Assessment; Validation; Thyroid cancer; Module of the M. D. Anderson Symptom Inventory; QUALITY-OF-LIFE; INSTRUMENTS; WITHDRAWAL; THYROXINE; VERSION;
D O I
10.1159/000178809
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The M. D. Anderson Symptom Inventory (MDASI) and its modules measure common symptoms related to cancer and its treatment. We report the development and initial validation of the MDASI-Thyroid Cancer module (MDASI-THY). Methods: A list of thyroid-cancer-specific symptoms was generated through focus groups and interviews with thyroid cancer patients, clinicians and researchers. These MDASI-THY items were added to the original MDASI and administered to 60 patients with thyroid cancer. Symptom prevalence and severity were evaluated, along with the reliability and content, construct and known-group validity of the MDASI-THY. Results: Cognitive debriefing performed on a subset of patients indicated that the MDASI-THY items were clear, concise, relevant and easy to understand. Fatigue, drowsiness, sleep disturbance, distress and difficulty remembering were the 5 most prevalent and severe symptoms. Twenty-eight percent of patients had moderate to severe fatigue (>= 5 on a 0-10 scale). Average severity was 1.28 and 1.29 for the symptom and interference subscales, respectively. MDASI-THY symptoms were severer for patients with poorer performance status. Cronbach alpha-values were 0.76, 0.85 and 0.92 for the thyroid-specific symptom items, core symptom subscale and interference subscale, respectively. Conclusions: This study demonstrates preliminary evidence for the validity and reliability of the MDASI-THY. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:59 / 68
页数:10
相关论文
共 50 条
  • [1] Validation of the M. D. Anderson Symptom Inventory multiple myeloma module
    Jones, Desiree
    Vichaya, Elisabeth G.
    Wang, Xin Shelley
    Williams, Loretta A.
    Shah, Nina D.
    Thomas, Sheeba K.
    Johnson, Valen E.
    Champlin, Richard E.
    Cleeland, Charles S.
    Mendoza, Tito R.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [2] Validation of the M. D. Anderson Symptom Inventory multiple myeloma module
    Desiree Jones
    Elisabeth G Vichaya
    Xin Shelley Wang
    Loretta A Williams
    Nina D Shah
    Sheeba K Thomas
    Valen E Johnson
    Richard E Champlin
    Charles S Cleeland
    Tito R Mendoza
    Journal of Hematology & Oncology, 6
  • [3] Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer
    Sailors, Mary H.
    Bodurka, Diane C.
    Gning, Ibrahima
    Ramondetta, Lois M.
    Williams, Loretta A.
    Mendoza, Tito R.
    Agarwal, Sonika
    Sun, Charlotte C.
    Cleeland, Charles S.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (02) : 323 - 328
  • [4] Psychometric Validation of the M. D. Anderson Symptom Inventory-Head and Neck Module in the Spanish Language
    Sanchez, Daniel
    Chala, Andres
    Alvarez, Andres
    Payan, Catalina
    Mendoza, Tito
    Cleeland, Charles
    Sanabria, Alvaro
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (06) : 1055 - 1061
  • [5] Assessing symptom distress in cancer patients - The M. D. Anderson Symptom Inventory
    Cleeland, CS
    Mendoza, TR
    Wang, XS
    Chou, C
    Harle, MT
    Morrissey, M
    Engstrom, MC
    CANCER, 2000, 89 (07) : 1634 - 1646
  • [6] Measuring the Symptom Burden of Lung Cancer: The Validity and Utility of the Lung Cancer Module of the M. D. Anderson Symptom Inventory
    Mendoza, Tito R.
    Wang, Xin Shelley
    Lu, Charles
    Palos, Guadalupe R.
    Liao, Zhongxing
    Mobley, Gary M.
    Kapoor, Shitij
    Cleeland, Charles S.
    ONCOLOGIST, 2011, 16 (02) : 217 - 227
  • [7] Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson Symptom Inventory, head and neck module
    Rosenthal, David I.
    Mendoza, Tito R.
    Chambers, Mark S.
    Asper, Joshua A.
    Gning, Ibrahima
    Kies, Merrill S.
    Weber, Randal S.
    Lewin, Jan S.
    Garden, Adam S.
    Ang, K. Kian
    Wang, Xin S.
    Cleeland, Charles S.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2007, 29 (10): : 923 - 931
  • [8] Filipino version of the M. D. Anderson symptom inventory: Validation and multisymptom measurement in cancer patients
    Wang, Xin Shelley
    Laudico, Adriano V.
    Guo, Hong
    Mendoza, Tito R.
    Matsuda, Maria Lourdes
    Yosuico, Victor D.
    Fragante, Edilberto P.
    Cleeland, Charles S.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 31 (06) : 542 - 552
  • [9] Greek M. D. Anderson Symptom Inventory: Validation and utility in cancer patients
    Mystakidou, K
    Cleeland, C
    Tsilika, E
    Katsouda, E
    Primikiri, A
    Parpa, E
    Vlahos, L
    Mendoza, T
    ONCOLOGY, 2004, 67 (3-4) : 203 - 210
  • [10] Validation and Application of a Module of the M. D. Anderson Symptom Inventory for Measuring Multiple Symptoms in Patients With Gastrointestinal Cancer (the MDASI-GI)
    Wang, Xin Shelley
    Williams, Loretta A.
    Eng, Cathy
    Mendoza, Tito R.
    Shah, Nyma A.
    Kirkendoll, Karyn J.
    Shah, Pankil K.
    Trask, Peter C.
    Palos, Guadalupe R.
    Cleeland, Charles S.
    CANCER, 2010, 116 (08) : 2053 - 2063